Loading patent…
AssigneeMati Therapeutics Inc.
InventorsDeepank Utkhede, JR., Robert Shimizu, Rachna Jain, Stephen Boyd, Hanson S Gifford, Eugene De Juan, Cary Reich
Estimating the term…
A solid drug core insert can be manufactured by injecting a liquid mixture comprising a therapeutic agent and a matrix precursor into a sheath body. The injection can be conducted at subambient temperatures. The mixture is cured to form a solid drug-matrix core. The therapeutic agent can be a liquid at about room temperature that forms a dispersion of droplets in the matrix material. A surface of the solid drug core is exposed, for example by cutting the tube, and the exposed surface of the solid drug core releases therapeutic quantities of the therapeutic agent when implanted into the patient. In some embodiments, the insert body inhibits release of the therapeutic agent, for example with a material substantially impermeable to the therapeutic agent, such that the therapeutic quantities are released through the exposed surface, thereby avoiding release of the therapeutic agent to non-target tissues.
1-41. (canceled)
An ocular implant for topical delivery of at least one therapeutic agent to an eye for an extended period of time, comprising:
A composition comprising a polymer matrix and a therapeutic agent, wherein the therapeutic agent is uniformly and homogenously dispersed in the matrix and wherein the composition is adapted to release the therapeutic agent at therapeutic levels to the eye for at least one month and wherein the composition is configured to be placed between conjunctiva tissue in a cul-de-sac of the eyelid and does not comprise a sheath body, and wherein the composition comprises a circular cross section.
An ocular implant for topical delivery of at least one therapeutic agent to an eye for an extended period of time, comprising:
Dependencies are inferred from the claim text.